Glaxo to take full control of Cellzome
Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.
Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.
Glaxo, which currently owns just under one fifth of Cambridge-based Cellzome, is paying £61m in cash to buy up the rest of the company, which will become part of Glaxo's research and development (R&D) organisation.
Cellzome's proteomics technologies can be used throughout the drug discovery process from screening to selectivity profiling of compounds in different cells and also in patient samples.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists the opportunity to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.
Glaxo and Cellzome have two active early stage research collaborations using these discovery capabilities within the immune-inflammation therapy area.
Simultaneous with the acquisition, Cellzome shareholders, including Glaxo, intend to create a spin-off company, which would hold the rights to certain of Cellzome's assets and activities that Glaxo does not want as part of its drugs development pipeline.
JH
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?
Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
By Kalpana Fitzpatrick Published
-
What does Rachel Reeves’s plan for growth mean for UK investors?
Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
By Katie Williams Published